Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Capital Expenditures came in at -$44000.0 in Q1 2026, little changed YoY from -$44000.0 in Q1 2025, and little changed on a QoQ basis from -$44000.0 in Q4 2025.
Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Capital Expenditures data on file, last reported at -$44000.0 in Q1 2026.
- Quarterly Capital Expenditures changed 0.0% year-over-year to -$44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$176000.0 (down 185.85% YoY) and the FY2025 annual result came in at -$176000.0, down 170.68% from the prior year.
- Capital Expenditures held at -$44000.0 in Q1 2026, from -$44000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $337000.0 in Q2 2024 to a low of -$44000.0 in Q3 2024.
- A 5-year average of $21166.7 and a median of -$44000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 121.45% — and 2024, when it sank 233.33%.
- Tracing BDTX's Capital Expenditures over 5 years: stood at $192000.0 in 2022, then tumbled by 82.81% to $33000.0 in 2023, then slumped by 233.33% to -$44000.0 in 2024, then changed by 0.0% to -$44000.0 in 2025, then changed by 0.0% to -$44000.0 in 2026.
- The last three Capital Expenditures figures came in at -$44000.0 (Q1 2026), -$44000.0 (Q4 2025), and -$44000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 256,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256,000.00 |
| Jun 30, 2026 | 256,000.00 |
| Mar 31, 2026 | -44,000.00 |
| Mar 31, 2026 | -44,000.00 |
| Dec 31, 2025 | -44,000.00 |
| Dec 31, 2025 | -44,000.00 |
| Sep 30, 2025 | -44,000.00 |
| Sep 30, 2025 | -44,000.00 |
| Jun 30, 2025 | -44,000.00 |
| Jun 30, 2025 | -44,000.00 |
| Mar 31, 2025 | -44,000.00 |
| Mar 31, 2025 | -44,000.00 |
| Dec 31, 2024 | -44,000.00 |
| Dec 31, 2024 | -44,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Jun 30, 2024 | 337,000.00 |
| Jun 30, 2024 | 337,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |